Fremont, United States
Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy profiles, but altering their delivery profile using the Company’s proprietary transdermal system.
The Company’s goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action. Zosano Pharma has developed its proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.
The Company’s system offers rapid and consistent drug delivery, improved ease of use and room-temperature stability, all of which are benefits that the Company believes are often unavailable using oral formulations or injections and offer important therapeutic and practical advantages that address unmet needs with large patient populations.
Zosano Pharma was founded in 2006 and is headquartered in the United States.
The company's last investment was a $15.40M Post-IPO Debt investment at 08 February 2022.
